Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Interest Paid, Excluding Capitalized Interest, Operating Activity

Interest Paid, Excluding Capitalized Interest, Operating Activity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity?
BioCryst Pharmaceuticals (BCRX) reported interest paid, excluding capitalized interest, operating activity of $6.08M in Q1 2026.
How has BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity changed year-over-year?
BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity decreased by 33.5% year-over-year, from $9.15M to $6.08M.
What is the long-term trend for BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's interest paid, excluding capitalized interest, operating activity has grown at a 126.6% compound annual growth rate (CAGR), from $900K to $23.74M.